NEW YORK, Feb. 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysishttp://www.reportlinker.com/p02029807/PharmaPoint-Epilepsy---Global-Drug-Forecast-and-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis

Summary

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.

Highlights

Key Questions Answered

- Even with more than 20 AEDs on the market, there are still ~20% refractory patients. Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the epilepsy market?- Several brands of AEDs are due for patent expiry. How will the patent expiries impact the epilepsy therapeutics market? - The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?- What governmental changes are likely to change the epilepsy treatment landscape in the markets researched? Which is the biggest growth market globally?

Key Findings

- New market entrants particularly Fycompa, Trobalt/Potiga and brivaracetam will increase competitiveness and cannibalize sales of existing AEDs.- Drivers for market growth will include the introduction of the newer epilepsy drugs into the Asian market, particularly in Japan.- Government cost-cutting measures will negatively impact epilepsy drug market in the EU

Scope

- Overview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized epilepsy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including ion channel modulators, GABA modulators, glutamate receptor antagonists, inflammation inhibitors, synaptic and gap junction blockers, sigma receptor agonists and acetylcholine modulators. - Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Track drug sales in the global epilepsy therapeutics market from 2012-2022.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.1 Table of Contents1 Table of Contents 81.1 List of Tables 151.2 List of Figures 202 Introduction 212.1 Catalyst 212.2 Upcoming Related Reports 223 Disease Overview 233.1 Classification of Seizures 253.2 Etiology and Pathophysiology 263.2.1 Etiology 263.2.2 Pathophysiology 293.2.3 Prognosis 343.2.4 Quality of Life 354 Epidemiology 364.1 Risk Factors and Comorbidities 364.1.1 Risk factors in newborns often include brain malformations and lack of oxygen 364.1.2 Genetic factors and head trauma are risk factors in adults and children 364.1.3 Common seizure triggers include lack of sleep, stress, and photosensitivity 374.1.4 Epilepsy comorbidities in adults and children include pain disorders 374.1.5 Anxiety and depression are major epilepsy comorbidities 374.1.6 Epilepsy with a known cause can be prevented by the avoidance of head injuries 384.2 Global Trends 384.2.1 United States 394.2.2 5EU Markets (France, Germany, Italy, Spain, and the UK) 404.2.3 Asia 414.3 Forecast Methodology 434.3.1 Sources Used 444.3.2 Forecast Assumptions and Methods 494.3.3 Sources Not Used 514.4 Epidemiologic Forecast 524.4.1 Total Active Prevalent Cases of Epilepsy 524.4.2 Total Lifetime Prevalent Cases of Epilepsy 544.4.3 Age-Specific Total Active Prevalent Cases of Epilepsy 564.4.4 Gender-Specific Total Active Prevalent Cases of Epilepsy 574.4.5 Seizure-Specific Total Active Prevalent Cases of Epilepsy 584.5 Discussion 594.5.1 Conclusion on Epidemiological Trends 594.5.2 Limitations of the Analysis 604.5.3 Strengths of the Analysis 605 Disease Management 615.1 Diagnosis 615.2 Treatment Guidelines 625.3 Clinical Practice 635.4 US 695.4.1 Diagnosis 695.4.2 Clinical Practice 715.5 UK 745.5.1 Diagnosis 745.5.2 Clinical Practice 755.6 France 765.6.1 Diagnosis 765.6.2 Clinical Practice 775.7 Germany 785.7.1 Diagnosis 785.7.2 Clinical Practice 795.8 Spain 815.8.1 Diagnosis 815.8.2 Clinical Practice 825.9 Italy 835.9.1 Diagnosis 835.9.2 Clinical Practice 845.10 Japan 855.10.1 Diagnosis 855.10.2 Clinical Practice 865.11 India 875.11.1 Diagnosis 875.11.2 Clinical Practice 875.12 China 895.12.1 Diagnosis 895.12.2 Clinical Practice 916 Competitive Assessment 936.1 Overview 936.2 Strategic Competitor Assessment 946.3 Product Profiles - Major Brands 976.3.1 Keppra (levetiracetam) 976.3.2 Lamictal (lamotrigine) 1026.3.3 Lyrica (pregabalin) 1076.3.4 Vimpat (lacosamide) 1116.3.5 Zonegran (zonisamide) 1156.3.6 Banzel/Inovelon (rufinamide) 1206.3.7 Trobalt/Potiga (retigabine/ezogabine) 1246.3.8 Zebinix (eslicarbazepine acetate) 1276.3.9 Fycompa (perampanel) 1316.3.10 Older-Generation AEDs 1347 Opportunity and Unmet Need 1367.1 Overview 1367.2 Unmet Needs 1377.2.1 Refractory Epilepsy 1377.2.2 Safety/Side Effect Profiles 1377.2.3 Curative/Disease-Modifying Agents 1387.2.4 Predictive Tools and Need for More Directed Treatments 1397.2.5 Improved Preclinical Models and Clinical Trial Paradigms 1397.2.6 Treatment Gap 1407.3 Unmet Needs Gap Analysis 1417.4 Opportunities 1427.4.1 Disease-Modifying Agents 1427.4.2 Improved Preclinical Models and Clinical Trial Paradigms 1427.4.3 Treatment Gap 1428 Pipeline Assessment 1438.1 Overview 1438.2 Clinical Trial Mapping 1438.2.1 Clinical Trials by Country 1438.3 Clinical Trials by Phase and Trial Status 1458.4 Strategic Pipeline Assessment 1468.5 Pipeline by Phases of Development 1478.5.1 Phase III Pipeline 1478.5.2 Phase III Pipeline - Reformulations/New Delivery Systems 1488.5.3 Phase IIb Pipeline 1488.5.4 Phase II Pipeline 1498.5.5 Phase I Pipeline 1498.5.6 Preclinical Pipeline 1508.5.7 Discovery Pipeline 1518.6 Pipeline by Mechanism of Action 1518.7 Promising Drugs in Clinical Development 1538.7.1 Brivaracetam 1548.7.2 Ganaxolone 1578.7.3 VX-765 1619 Current and Future Players 1659.1 Overview 1659.2 Trends in Corporate Strategy 1689.3 Company Profiles 1699.3.1 UCB 1699.3.2 Eisai 1719.3.3 Pfizer 1729.3.4 GlaxoSmithKline 1749.3.5 Novartis 1759.3.6 Abbott 1779.3.7 Dainippon Sumitomo Pharma 17910 Market Outlook 18110.1 Global Markets 18110.1.1 Forecast 18110.1.2 Drivers and Barriers - Global Issues 18410.2 United States 18610.2.1 Forecast 18610.2.2 Key Events 18910.2.3 Drivers and Barriers 18910.3 France 19110.3.1 Forecast 19110.3.2 Key Events 19410.3.3 Drivers and Barriers 19410.4 Germany 19510.4.1 Forecast 19510.4.2 Key Events 19910.4.3 Drivers and Barriers 19910.5 Italy 20110.5.1 Forecast 20110.5.2 Key Events 20410.5.3 Drivers and Barriers 20410.6 Spain 20610.6.1 Forecast 20610.6.2 Key Events 20910.6.3 Drivers and Barriers 20910.7 United Kingdom 21010.7.1 Forecast 21010.7.2 Key Events 21410.7.3 Drivers and Barriers 21410.8 Japan 21610.8.1 Forecast 21610.8.2 Key Events 21910.8.3 Drivers and Barriers 21910.9 India 22110.9.1 Forecast 22110.9.2 Key Events 22410.9.3 Drivers and Barriers 22410.10 China 22610.10.1 Forecast 22610.10.2 Key Events 22910.10.3 Drivers and Barriers 22911 Appendix 23111.1 Bibliography 23111.2 Abbreviations 24411.3 Methodology 24711.4 Forecasting Methodology 24711.4.1 Prevalent Epilepsy Patients 24711.4.2 Percent Drug-Treated Patients 24811.4.3 Drugs Included in Each Therapeutic Class Based on MOA 24811.4.4 Launch Dates and Patent and Market Exclusivity Expiry Dates 24911.4.5 General Pricing Assumptions 25111.4.6 Individual Drug Assumptions 25211.4.7 Generic Erosion 26611.4.8 Pricing of Pipeline Agents 26611.5 Physicians and Specialists Included in this Study 26711.6 Primary Research - Prescriber Survey 26811.7 About the Authors 26911.7.1 Authors 26911.7.2 Epidemiologist 27011.7.3 Global Head of Healthcare 27011.8 About GlobalData 27111.9 Contact Us 27111.10 Disclaimer 271

List of Tables

Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification) 24Table 2: Classification of Seizures 25Table 3: Etiology of Epilepsy According to Age 26Table 4: Etiology of Partial Seizures 27Table 5: Etiology of Generalized Seizures 28Table 6: Some of the Genes Involved in Epilepsy 33Table 7: Nine Markets, Sources for Prevalent Cases of Epilepsy Data 44Table 8: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022 53Table 9: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022 55Table 10: Summary of Diagnostic Tools for Epilepsy 61Table 11: Treatment Guidelines for Epilepsy 62Table 12: AED Options by Seizure Type 66Table 13: Top Three AEDs Prescribed for Epilepsy by Market 67Table 14: Types of Epilepsy Surgery 68Table 15: Types of Epilepsy Surgery 70Table 16: US, Most-Prescribed First-Line and Second-Line AEDs 71Table 17: UK, Epilepsy Patient Referrals to Neurologist 74Table 18: UK, Most-Prescribed First-Line and Second-Line AEDs 75Table 19: France, Epilepsy Patient Referrals to Neurologist 76Table 20: France, Most-Prescribed First-Line and Second-Line AEDs 77Table 21: Germany, Epilepsy Patient Referrals to Neurologist 79Table 22: Germany, Most-Prescribed First-Line and Second-Line AEDs 80Table 23: Spain, Epilepsy Patient Referrals to Neurologist 81Table 24: Spain, Most-Prescribed First-Line and Second-Line AEDs 82Table 25: Italy, Epilepsy Patient Referrals to Neurologist 83Table 26: Italy, Most-Prescribed 1st-line and 2nd-line AEDs 84Table 27: Japan, Epilepsy Patient Referrals to Neurologist 85Table 28: Japan, Epilepsy Patient Referrals to Neurologist 86Table 29: Japan, Epilepsy Patient Referrals to Neurologist 87Table 30: India, Most-Prescribed 1st-line and 2nd-line AEDs 88Table 31: India, Most-Prescribed 1st-line and 2nd-line AEDs 90Table 32: China, Most-Prescribed First-Line and Second-Line AEDs 91Table 33: Leading Treatments for Epilepsy, 2012 97Table 34: Product Profile - Keppra 98Table 35: Keppra SWOT Analysis, 2012 100Table 36: Global Sales Forecasts ($m) for Keppra (levetiracetam), 2012-2022 101Table 37: Product Profile - Lamictal 102Table 38: Lamictal SWOT Analysis, 2012 105Table 39: Global Sales Forecasts ($m) for Lamictal (lamotrigine), 2012-2022 106Table 40: Product Profile - Lyrica 107Table 41: Lyrica SWOT Analysis, 2012 109Table 42: Global Sales Forecasts ($m) for Lyrica (pregabalin), 2012-2022 110Table 43: Product Profile - Vimpat 111Table 44: Vimpat SWOT Analysis, 2012 113Table 45: Global Sales Forecasts ($m) for Vimpat (lacosamide), 2012-2022 114Table 46: Product Profile - Zonegran 115Table 47: Zonegran SWOT Analysis, 2012 117Table 48: Global Sales Forecasts ($m) for Zonegran (zonisamide), 2012-2022 119Table 49: Product Profile - Banzel/Inovelon 120Table 50: Banzel/Inovelon SWOT Analysis, 2012 122Table 51: Global Sales Forecasts ($m) for Banzel/Inovelon (rufinamide), 2012-2022 123Table 52: Product Profile - Trobalt/Potiga 124Table 53: Trobalt/Potiga SWOT Analysis, 2012 126Table 54: Global Sales Forecasts ($m) for Trobalt/Potiga (retigabine/ezogabine), 2012-2022 127Table 55: Product Profile - Zebinix 128Table 56: Zebinix SWOT Analysis, 2012 130Table 57: Global Sales Forecasts ($m) for Zebinix (eslicarbazepine acetate), 2012-2022 131Table 58: Product Profile - Fycompa 132Table 59: Fycompa SWOT Analysis, 2012 133Table 60: Global Sales Forecasts ($m) for Fycompa (perampanel), 2012-2022 134Table 61: Summary of Minor Drug Classes, 2012 135Table 62: Overall Unmet Needs - Current Level of Attainment 136Table 63: Clinical Unmet Needs - Gap Analysis, 2012 141Table 64: Epilepsy - Clinical Trials by Phase and Status, 2012 145Table 65: Epilepsy - Phase III Pipeline, 2012 147Table 66: Epilepsy - Phase III Pipeline (Reformulations), 2012 148Table 67: Epilepsy - Phase IIb Pipeline, 2012 148Table 68: Epilepsy - Phase II Pipeline, 2012 149Table 69: Epilepsy - Phase I Pipeline, 2012 149Table 70: Epilepsy - Preclinical Pipeline, 2012 150Table 71: Epilepsy - Discovery Pipeline, 2012 151Table 72: Comparison of MOA of Drugs in Development for Epilepsy, 2012 152Table 73: Epilepsy - Promising Drugs in Clinical Development 153Table 74: Product Profile - Brivaracetam 154Table 75: Brivaracetam SWOT Analysis, 2012 156Table 76: Global Sales Forecasts ($m) for Brivaracetam, 2012-2022 157Table 77: Product Profile - Ganaxolone 158Table 78: Ganaxolone SWOT Analysis, 2012 160Table 79: Global Sales Forecasts ($m) for Ganaxolone, 2012-2022 161Table 80: Product Profile - VX-765 162Table 81: VX-765 SWOT Analysis, 2012 163Table 82: Global Sales Forecasts ($m) for VX-765, 2012-2022 164Table 83: Key Companies in the Epilepsy Market, 2012 166Table 84: UCB's Epilepsy Portfolio Assessment, 2012 170Table 85: UCB SWOT Analysis, 2012 170Table 86: Eisai's Epilepsy Portfolio Assessment, 2012 171Table 87: Eisai SWOT Analysis, 2012 172Table 88: Pfizer's Epilepsy Portfolio Assessment, 2012 173Table 89: Pfizer SWOT Analysis, 2012 173Table 90: GlaxoSmithKline's Epilepsy Portfolio Assessment, 2012 174Table 91: GlaxoSmithKline SWOT Analysis, 2012 175Table 92: Novartis' Epilepsy Portfolio Assessment, 2012 176Table 93: Novartis SWOT Analysis, 2012 176Table 94: Abbott's Epilepsy Portfolio Assessment, 2012 178Table 95: Abbott SWOT Analysis, 2012 178Table 96: Dainippon Sumitomo's Epilepsy Portfolio Assessment, 2012 179Table 97: Dainippon Sumitomo SWOT Analysis, 2012 180Table 98: Global Sales Forecasts ($m) for Epilepsy, 2012-2022 182Table 99: Global Epilepsy Market - Drivers and Barriers, 2012-2022 184Table 100: Sales Forecasts ($m) for Epilepsy in the United States, 2012-2022 187Table 101: Key Events Impacting Sales for Epilepsy in the United States, 2012-2022 189Table 102: Epilepsy Market in the US - Drivers and Barriers, 2012-2022 189Table 103: Sales Forecasts ($m) for Epilepsy in France, 2012-2022 192Table 104: Key Events Impacting Sales for Epilepsy in France, 2012-2022 194Table 105: Epilepsy Market in France - Drivers and Barriers, 2012-2022 194Table 106: Sales Forecasts ($m) for Epilepsy in Germany, 2012-2022 197Table 107: Key Events Impacting Sales for Epilepsy in Germany, 2012-2022 199Table 108: Epilepsy Market in Germany - Drivers and Barriers, 2012-2022 199Table 109: Sales Forecasts ($m) for Epilepsy in Italy, 2012-2022 202Table 110: Key Events Impacting Sales for Epilepsy in Italy, 2012-2022 204Table 111: Epilepsy Market in Italy - Drivers and Barriers, 2012-2022 204Table 112: Sales Forecasts ($m) for Epilepsy in Spain, 2012-2022 207Table 113: Key Events Impacting Sales for Epilepsy in Spain, 2012-2022 209Table 114: Epilepsy Market in Spain - Drivers and Barriers, 2012-2022 209Table 115: Sales Forecasts ($m) for Epilepsy in the United Kingdom, 2012-2022 212Table 116: Key Events Impacting Sales for Epilepsy in the United Kingdom, 2012-2022 214Table 117: Epilepsy Market in the UK - Drivers and Barriers, 2012-2022 214Table 118: Sales Forecasts ($m) for Epilepsy in Japan, 2012-2022 217Table 119: Key Events Impacting Sales for Epilepsy in Japan, 2012-2022 219Table 120: Epilepsy Market in Japan - Drivers and Barriers, 2012-2022 219Table 121: Sales Forecasts ($m) for Epilepsy in India, 2012-2022 222Table 122: Key Events Impacting Sales for Epilepsy in India, 2012 224Table 123: Epilepsy Market in India - Drivers and Barriers, 2012-2022 224Table 124: Sales Forecasts ($m) for Epilepsy in China, 2012-2022 227Table 125: Key Events Impacting Sales for Epilepsy in China, 2012 229Table 126: Epilepsy Market in China - Drivers and Barriers, 2012-2022 229Table 127: Key Launch Dates 249Table 128: Key Patent Expiries and Market Exclusivity Expiries* 250Table 129: Physicians Surveyed, By Country 268

1.2 List of FiguresFigure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation 30Figure 2: Mechanisms of Action of AEDs at the Synapse 32Figure 3: Nine Markets, Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022 53Figure 4: Nine Markets, Total Lifetime Prevalent Cases of Epilepsy, All Ages, Male and Female, Selected Years, 2012-2022 55Figure 5: Nine Markets, Age-Specific Total Active Prevalent Cases of Epilepsy, All Ages, Male and Female, 2012 56Figure 6: Nine Markets, Gender-Specific Total Active Prevalent Cases of Epilepsy, All Ages, 2012 57Figure 7: Nine Markets, Seizure-Specific Proportions of Epilepsy, All Ages, Male and Female, 2012 58Figure 8: AED Selection Based on Comorbidity 65Figure 9: Epilepsy Therapeutics -Clinical Trials by Country, 2012 144Figure 10: Epilepsy - Pipeline by MOA, 2012 152Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Epilepsy, 2012-2022 153Figure 12: Company Portfolio Gap Analysis in Epilepsy, 2012-2022 167Figure 13: Global Sales for Epilepsy by Region, 2012-2022 183Figure 14: Sales for Epilepsy in the United States by Drug Class, 2012-2022 188Figure 15: Sales for Epilepsy in France by Drug Class, 2012-2022 193Figure 16: Sales for Epilepsy in Germany by Drug Class, 2012-2022 198Figure 17: Sales for Epilepsy in Italy by Drug Class, 2012-2022 203Figure 18: Sales for Epilepsy in Spain by Drug Class, 2012-2022 208Figure 19: Sales for Epilepsy in the United Kingdom by Drug Class, 2012-2022 213Figure 20: Sales for Epilepsy in Japan by Drug Class, 2012-2022 218Figure 21: Sales for Epilepsy in India by Drug Class, 2012-2022 223Figure 22: Sales for Epilepsy in China by Drug Class, 2012-2022 228

To order this report: PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysishttp://www.reportlinker.com/p02029807/PharmaPoint-Epilepsy---Global-Drug-Forecast-and-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKShttp://www.reportlinker.com